drugset
drugset / Trial / NCT04072458

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

NCT04072458 ↗

Phase 1 Active not recruiting 30 enrolled Bio-Path Holdings, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients with a diagnosis of relapsed or refractory lymphoid malignancies are expected to participate.

Timeline

Start
2020-11-05
Primary completion
2025-04
Completion
2025-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BP1002 Antisense oligonucleotide 20 mg/m2 Intravenous
Subject BP1002 Antisense oligonucleotide 40 mg/m2 Intravenous

Indications

Hodgkins lymphoma Waldenstrom macroglobulinemia chronic lymphocytic leukemia/small lymphocytic lymphoma diffuse large B-cell lymphoma follicular lymphoma mantle cell lymphoma marginal zone lymphoma peripheral T-cell lymphoma, not otherwise specified primary cutaneous T-cell lymphoma